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Abstract 
 
Huntington’s disease is an inherited neurodegenerative disorder. It belongs to the 
polyQ accumulation disease with mutant Huntingtin protein. The mutant Huntingtin 
has expended CAG triplet repeats which make it easily accumulate. However, the 
exact mechanism causing Huntington’s disease pathophysiology is unknown. Here, I 
propose that Huntington’s disease is an autoimmune disease. During childhood, 
there is Treg cells from thymus to prevent autoimmune reaction against the mutant 
Huntingtin. When the patient grows older, the accumulated mutant Huntingtin 
triggers TH17 related inflammatory reaction via heat shock proteins and toll-like 
receptor activation. Then, TH17 related cytokines such as TNFα, IL1, and IL6 cause 
neuron degeneration via activating apoptotic cascade. Once we know the 
pathogenesis of Huntington’s disease, we can use immunology knowledge to develop 
preventive or therapeutic strategies to cope with this detrimental disorder. 
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Introduction  
 
Huntington’s disease is a common inherited neurodegenerative disorder. Involuntary 
chorea is the main symptom of this disorder. It usually develops in later adulthood. 
There is an anticipation phenomenon of Huntington’s disease. The offspring of a 
Huntington’s disease patient will develop this disease earlier than his parents. The 
key gene of Huntington’s disease is the mutant Huntingtin. The mutant Huntingtin 
has expanded multiple CAG triplets in its exon. When the Huntingtin gene is 
translated, it will express multiple glutamines (polyQ). The polyQ protein will cause 
itself insoluble and easily accumulated in neuron.(Scherzinger, Lurz et al. 1997) 
However, it is still unknown why the polyQ protein will cause neurodegeneration. 
Here, I propose evidences showing that Huntington’s disease is actual a TH17 
autoimmune disease against the mutant Huntingtin by microarray analysis. During 
childhood, there is Treg cells from thymus that can suppress the autoimmunity 
against the mutant polyQ Huntingtin. When the patient grows older with the 
disappearance of thymus and Huntingtin specific Treg cells, there is a chance to 
develop autoimmune T and B cells against the mutant insoluble accumulated 
Huntingtin. This autoimmune disease is a TH17 dominant autoimmunity. 
Accumulated Huntingtin can activate heat shock proteins to bind to toll-like receptor 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
12
9.
1 
: P
os
te
d 
21
 J
ul
 2
01
1
2&4 to trigger TH17 cytokines. The vital TH17 cytokines such as IL-1, IL-6, and TNFα 
can trigger apoptosis cascade in neuron to induce neurodegeneration. Since the 
mutant Huntingtin is mainly expressed in caudate nucleus, the symptom of chorea 
develops after the neurons there are destroyed. Here, I use two microarray dataset 
of Huntington’s disease patients to show the up-regulated genes. One is the 
peripheral blood mononuclear cell gene expression profile. The other is caudate 
nucleus gene expression profile. We can find that ubiquitin-proteasome processing 
system is down-regulated in caudate nucleus. Heat shock proteins are differentially 
expressed in caudate nucleus. Both in caudate nucleus and peripheral leukocytes, the 
TH17 related cytokines, transcription factors, effector molecules, and 
casapse-apoptosis molecules are up-regulated. It suggests that Hungtington’s disease 
is actually a TH17 dominant autoimmune disease. I think this pathophysiology can 
also apply for other polyQ (CAG triplet) disorders as well.   
 
Material and Methods  
 
Microarray datasets of Huntington’s disease 
 
In this paper, I incooperate two microarray datasets for analysis. The fist one is 
peripheral blood mononuclear cell gene expression profiles in Huntington’s disease 
patient. The dataset GSE8762 is available in GEO website. Dr. Runne published the 
research results of peripheral blood biomarkers for Huntington’s disease in 
PNAS.(Runne, Kuhn et al. 2007) The second dataset(GSE3790) is caudate nucleus 
gene expression profiles in Huntington’s disease. Caudate nucleus is the major 
affected brain area.(Hodges, Strand et al. 2006)  
 
Statistical analysis 
 
RMA express software(UC Berkeley, Board Institute) is used to do normalization and 
to rule out the outliners of the above dataset. I rule out the potential outliners of 
samples due to the following criteria:  
1. Remove samples which have strong deviation in NUSE plot 
2. Remove samples which have broad spectrum in RLE value plot 
3. Remove samples which have strong deviation in RLE-NUSE mutiplot 
4. Remove samples which exceed 99% line in RLE-NUSE T2 plot 
 
Validation by RT-PCR 
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In Dr. Runne’s paper, RT-PCR analysis was done for selected genes such as AIM2, 
ACTB, AQP9, CD44, DAB2, DUSP1, HLA-DQA1, NXD1, NFKBIA, PPIF, PPP1R15A, 
PPP3CA, NRGN, RPLP, SLC14A1, TncRNA, ZBTB16, COX-2, IL-1B, IL-8, TNF-a, BCL-XL, 
TGF-b, HPRT, IER3, P2RS1, EGR1, MLH3, TNFRSF17, ACTB, PRKCB1, NDUFB2, and 
HPRT.(Runne, Kuhn et al. 2007) The results of RT-PCR are consistent with the results 
of microarray analysis. Thus, the microarray platforms and results are confirmed by 
RT-PCR validation. We can also use this microarray dataset to do further analysis.  
 
Result 
 
Down-regulation of ubiquitin-proteasomes and cyclophilin-FK506 binding proteins in 
caudate nucleus of Huntington’s patients 
 
We find out that many ubiquitin or proteasome related genes are down-regulated in 
caudate nucleus of Huntington’s disease. (Table 1 & 2) It has been reported that 
there is ubiquitin-proteasome function impairment in Huntington’s disease. The 
mutant huntingtin can inhibit the normal physiological function of 
ubiquitin-proteasome system in cells. Our findings also show that 
ubiquitin-proteasome system is down-regulated in mRNA levels in neurons of 
Huntington’s disease. In addition, the other important protein processing proteins 
such as FK506 binding proteins and cyclophilins are also down-regulated in caudate 
nucleus of Huntington’s disease patients. (Table 3). The results suggest that general 
protein processing system is down-regulated in neurons of Huntington’s disease. 
 
Up-regulation of MHC related genes in caudate nucleus of Huntington’s disease 
 
We find out that many MHC-related genes are up-regulated in the caudate nucleus 
neurons of Huntington’s disease patients.(Table 4) These MHC related genes are key 
genes to present antigens to other immune cells to generate immunity. Thus, it is 
likely that host immunity is generated in Huntington’s disease.   
 
Differential regulation of Toll-like receptor and heat shock protein genes in caudate 
nucleus of Huntington’s disease 
 
In caudate nucleus of Huntington’s disease patients, we can see differentially 
up-regulated heat shock protein genes.(Table 5) Besides, there are differential 
regulation of toll-like receptor genes in caudate neurons of Huntington’s patients. 
(Table 6) Although some heat shock proteins are down-regulated in caudate nucleus 
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of Huntington’s disease possibly due to the general down-regulation of protein 
processing machinery, many heat shock proteins including HSP70s are up-regulated 
in neurons of Huntington’s disease. TLR5, CD14, and TRAF3 are also up-regulated in 
Huntington’s disease. In addition, the negative Toll signaling molecule TOLLIP is 
down-regulated, and it suggests that the Toll-signaling is up-regulated in Huntington’s 
disease in general. Normally, HSP70 acting on CD14 or TLR5 responding can generate 
TH17 cytokines against extracellular bacteria. Thus, we can infer that TH17 immunity 
is likely to be initiated via heat shock proteins and Toll-like receptors. 
 
Up-regulation of Huntingtin related genes and down-regulation of alpha-synuclein 
and APP genes in caudate nucleus of Huntington’s disease 
 
Since mutant Huntingtin is supposed to be the autoantigen in brain, we can also find 
out that Huntingtin related genes are up-regulated in caudate nucleus of 
Huntington’s disease. APP gene is the key molecule in Alzheimer’s disease, and alpha 
synuclein is the key molecule in Parkinson disease. Both APP and alpha synuclein are 
down-regulated in caudate nucleus of Huntington’s disease patients. (Table 7)  
 
Up-regulation of TH17 cytokines and their receptors in caudate nucleus of 
Huntington’s disease 
 
Although caudate nucleus neutrons are not immune cells, we can also look at their 
cytokine expression to see if there is special immunological pathway activation in 
Huntington’s disease. In addition, some papers have shown that neurons can also 
secrete cytokines responding to stimuli even the cytokine amount is not much. 
According to the microarray results, we find out that many TH17 related cytokines 
and their receptors are up-regulated in caudate nucleus neurons of Huntington’s 
disease patients.(Table 8) The date showed that TGF beta and its receptor, IL-6, TNF 
alpha and its receptor, M-CSF receptor, and IL-17 receptor are all up-regulated. 
Although IL-4 receptor, IFN gamma receptor, and IL-13 receptor are also up-regulated, 
key TH2 cytokines such IL-4, IL-5, and IL-13 are not up-regulated. Key TH1 cytokines 
such as IL-12 and IFN gamma and key TH9 (THαβ) cytokines such as IFNα, IFNβ, and 
IL-10 are not up-regulated, either. However, key TH17 cytokines: TGF beta and IL-6 
are significantly up-regulated. TGF beta plus IL-6 can fully initiate TH17 immunity.  
 
Up-regulation of TH17 related transcription factors in caudate nucleus of 
Huntington’s patients 
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We also find out that many TH17 related transcription factors are up-regulated in 
caudate nucleus of Huntington’s disease patients.(Table 9) CEBPD and CEBPB are 
transcription factors of TH17 immunity, and the two transcription factors are 
up-regulated in caudate nucleus of Huntington’s patients. AP-1, a TH17 dominant 
transcription factor, is also up-regulated including Jun and Fos in caudate nucleus of 
Huntington’s disease. STAT3, NFkBIA, and IKBKB are key transcription factors for 
driving TH17 immunity, and they all are up-regulated. STAT4, a key transcription 
factor for traditional TH1 immunity, is down-regulated in caudate nucleus of 
Huntington’s disease patients. 
 
Up-regulation of TH17 related effector molecules in caudate nucleus of Huntington’s 
disease patients 
 
In caudate nucleus of Huntington’s disease patients, many TH17 related effector 
molecules are up-regulated including complements, Fc receptors, and S100 binding 
proteins. (Table 10) Most of the complement components are up-regulated, and 
complements are major TH17 effector molecules. S100 binding proteins are key 
chemoattractants for neutrophils, major TH17 effector cells. Fc receptors including 
CD64 are also up-regulated, and these phagocyte related Fc receptors may enhance 
neutrophil and macrophage ADCC machinery. The above evidences all suggest that 
TH17 immunity is up-regulated in Huntington’s disease. 
 
Up-regulation of apoptosis molecules in caudate nucleus of Huntington’s disease 
patients 
 
In caudate nucleus of Huntington’s patients, many apoptosis molecules are 
up-regulated. (Table 11) These molecules can be up-regulated by TH17 cytokines 
such as IL-1 and TNF alpha. Fas inhibitory molecules and caspase 8 which is 
up-regulated by TNF alpha are up-regulated in caudate nucleus of Huntington’s 
disease.  
 
Up-regulation of TH17 related cytokines in peripheral leukocytes of Huntington’s 
disease patients 
 
In this microarray analysis, we find out that many TH17 related cytokines are 
up-regulated in peripheral leukocytes of Huntington’s disease patients.(Table 12) 
Among all of them, IL-1 and IL-8 are mostly highly up-regulated. These two cytokines 
are key effector cytokines in TH17 immunity. IL-1 plays an essential role in TH17 
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helper cell differentiation. Thrombospondin, an activator of TGF beta, is also 
up-regulated in peripheral leukocytes of Huntington’s patients. TGF beta is another 
key cytokine to drive TH17 differentiation. IRAK2 and IL-1 member 7 are also 
up-regulated in peripheral leukocytes of Huntington’s disease. In addition, many 
TH17 cytokine receptors are up-regulated including tumor necrosis factor receptor 
10b, IL-17 receptor E, and IL-22 receptor alpha1.  
 
Up-regulation of TH17 related transcription factors in peripheral leukocytes of 
Huntington’s disease patients 
 
In this analysis, I find that many TH17 driven transcription factors are up-regulated in 
peripheral leukocytes of Huntington’s disease patients. (Table 13) NFKBIA, NFKBIZ, 
and NFKB2 are up-regulated in Huntington’s disease. NFKBIA is the inhibitor of NFKB1. 
NFKB1 deficiency can cause hyperproduction of TH17 helper cells. In addition, 
NFKBIA and NFKBIZ are essential in TH17 immunological pathway development. 
NFKB2 is important in B cell homeostasis and proliferation. IKKB, the inhibitor of 
NFKB2, can suppress TH17 immunity related granulocytosis. Thus, NFKB2 also plays 
an important role in TH17 immunity. Fos antigen, forming AP-1 transcription factor, is 
also up-regulated after Huntington’s disease. AP-1 is another key transcription factor 
in TH17 immunity. Besides, up-regulated SMAD4 is the downstream molecule of TGF 
beta signaling, an important cytokine for TH17 initiation. 
 
Up-regulation of Th17 related effector molecules in peripheral leukocytes of 
Huntington’s disease patients 
 
In this study, I also find out that many TH17 related effector molecule up-regulation 
in Huntington’s disease patients. (Table 14) First of all, complement related genes are 
up-regulated including complement 8 gamma, decay accelerating factor, and CD46 
complement regulatory protein. Second, defensin beta, PGE receptor, mannosidase 
lysozyme, and IgA Fc receptor are up-regulated in leukocytes of Huntington’s patients. 
Third, chemokine such as CXCL2, CCL17, and CCL22 are up-regulated. Even CCL17 and 
CCL22 are not belonged to TH17 immunity, the highest up-regulated CXCL2 is the 
chemoattractant for TH17 effector neutrophils. Finally, many caspase genes are 
up-regulated including casapse 2, caspase 8, and caspase 10. These caspases are 
downstream molecules of TH17 cytokine TNF alpha and IL-1. All the above evidences 
show that TH17 immunity is dominant in Huntington’s disease. 
 
Discussion 
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 Huntington’s disease is inherited neurodegenerative disorder. Involuntary chorea is 
the chief symptom & sign. It is an autosomal dominant disease which is related to 
the Huntingtin mutation. Huntington’s disease is also a Trinucleotide Repeat Disorder 
that has multiple CAG repeats (coding glutamine) in the exon area. Then, the mutant 
Huntingtin can be translated into protein with polyglutamine tract (polyQ). The 
penetrance of Huntington’s disease is related to the copy number of the CAG repeats. 
If the CAG repeats are greater than 36, Huntington’s disease is very likely to happen. 
If the CAG repeats are greater than 40, there is a full penetrance to cause 
Huntington’s disease. The onset of Huntington’s disease is usually at 35-44 years-old. 
Even we know Huntingtin is the key player of Huntington’s disease, we still don’t 
understand the exact pathogenesis of Huntington’s disease.   
 
Huntingtin is mainly expressed in brain and testis. It is highly expressed in basal 
ganglia, especially striatum. The disease progression of Huntington’s disease is 
related to the damage of striatum. Caudate nucleus is the major subcomponent of 
striatum. After the destruction of striatum, Huntington’s patients will develop 
involuntary chorea. We know the mutant Huntingtin can be accumulated in the 
neurons of striatum. It can be in the cytosol or be linked to plasma membrane. CAG 
codes glutamine. We know the polyglutamine tract can cause Huntingtin protein to 
be insoluble and aggregated. In addition, polyglutamine can enhance Huntingtin to 
insert into plasma membrane lipid bilayer. In a paper, Huntingtin can interact with 
brain neuron membrane.(Suopanki, Gotz et al. 2006) The physiological function of 
Huntingtin is related to neurogenesis, and the polyQ tract of mutant Huntingtin 
doesn’t interfere with its normal function. It is also unlikely a sole mutant protein can 
cause neuron death. If mutant Huntingtin can cause neuron apoptosis, why can’t 
mutant Huntingtin induce neurodegeneration from early childhood or infancy? 
However, we don’t know why the polyglutamine (polyQ) tail of Huntingtin will cause 
Huntington’s disease. Here, I also propose an autoimmune mechanism for this 
neurodegenerative disorder. We know the increased CAG triplets can cause disease, 
but we still don’t know why CAG repeats can cause disease. Inflammation or 
autoimmunity can link the gap between increased DNA CAG triplets and 
neurodegeneration. During childhood or juvenile period, there should be Huntingtin 
specific Treg cells to suppress autoimmune reaction against the mutant Huntingtin. 
When the patients enter the adulthood with thymus atrophy, the Huntingtin specific 
Treg may be lost. In addition, the accumulated insoluble membrane-associated 
mutant Huntingtin can trigger host immune response. Another detrimental TH17 
autoimmunity happens. 
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 Although there is ubiquitin-proteasome system impairment associated with 
accumulated mutant Huntingtin, there are still molecular chaperons including heat 
shock protein up-regulation in Huntington’s disease.(Bence, Sampat et al. 2001) 
There are down-regulations of ubiquitin and proteasome genes during Huntington’s 
disease. Polyglutamine accumulation can suppress proteasomes.(Verhoef, Lindsten 
et al. 2002) We can see the differential regulation of heat shock proteins in caudate 
nucleus in Huntington’s disease. Molecular chaperons such as heat shock proteins 
can be up-regulated due to the accumulation of cytosolic proteins, especially 
Huntingtin. It is worth noting that several heat shock protein 70 genes are 
up-regulated in Huntington’s disease. In a R6/2 animal model, overexpression of heat 
shock protein doesn’t change the progression of Huntington’s disease. It means that 
heat shock protein up-regulation is not a protective but a contributing factor for the 
disease.(Hansson, Nylandsted et al. 2003) In addition, Toll-like receptor 5 and CD14 
are also up-regulated in Huntington’s disease. HSP70 can activate CD14 to induce 
TH17 cytokines such as IL-1, IL-6, and TNFα.(Freidin, Bennett et al. 1992; Asea, Kraeft 
et al. 2000; Gao and Tsan 2003; Lehnardt, Schott et al. 2008) IL-1 can in turns induce 
more heat shock protein production to cause a vicious cycle.(Welsh, Welsh et al. 
1991; Lehnardt, Schott et al. 2008) TLR5 usually reacts to bacteria flagellin to induce 
TH17 immunity. Thus, TH17 immunity is very possible to be induced in Huntington’s 
disease.   
 
We can look at the key immune transcription factors to see if TH17 immunological 
pathway is up-regulated. NFKBIA, NFKBIZ, NFKB2, Fos(AP-1), and SMAD4 are 
up-regulated in Huntington’s disease. There transcription factors are important in 
initiating TH17 immunity.(Chang, Lee et al. 2009; Schraml, Hildner et al. 2009; 
Okamoto, Iwai et al. 2010; Li, Ruan et al. 2011) NFkB plays a vital role in Huntingtin 
mediated neuro-toxicity.(Khoshnan, Ko et al. 2004) Based on my analysis, we find 
that there are also many major TH17 related cytokine up-regulation in Huntington’s 
disease. These cytokines and cytokine receptors include IL-1 beta, IL-8, TNF receptor 
member 10b, IL-1 family member7, interleukin 17 receptor E, and interleukin 22 
receptor alpha. In addition, although TGF beta receptor is down-regulated in 
Huntington’s disease, TGF beta activator, thrombospondin, is significantly 
up-regulated. IL-1 beta is also a key cytokine to induce TH17 
differentiation.(Schultz-Cherry and Murphy-Ullrich 1993; Acosta-Rodriguez, 
Napolitani et al. 2007; Chung, Chang et al. 2009) Although the expression levels of 
TGF beta receptor and IL-21 receptor are down-regulated, there are maximal 
up-regulation of IL-1 beta and IL-8. Besides, the chemokine CXCL2, chemoattractant 
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for neutrophils, is the most significantly up-regulated chemokine ligand in 
Huntington’s disease. There are also TH17 effector molecule up-regulation including 
defensin, complements, C-type lectin, prostaglandin receptor, lysozyme, and IgA Fc 
receptor. These above evidences all suggest that TH17 immunity is dominant in 
Huntington’s disease. Like other neurodegenerative disorder, the major TH17 
cytokines such as TNFα, IL-1, and IL-6 can activate caspase-apoptotic cascade to 
cause Wallerian degeneration.(Li, Li et al. 2001; Kebir, Kreymborg et al. 2007) TNFα 
and IL-1 can up-regulate caspases to cause neuron apoptosis.(Ona, Li et al. 1999; 
Sanchez, Xu et al. 1999; Maglione, Cannella et al. 2006) That is the pathophysiology 
of Huntington’s disease. 
 
Witebsky’s postulates are the standard criteria to decide if a disorder is an 
autoimmune disease. There are three requirements in Witebsky’s postulates: 1. 
Direct evidence from transfer of pathogenic antibody or T cells 2. Indirect evidence 
based on reproduction of the autoimmune disease in experimental animal 3. 
Circumstantial evidence from clinical clues. Then, I will use these criteria to check if 
Huntington’s disease fulfills the standard of autoimmune disorder. First, IgG 
autoanibody against brain caudate nucleus was detected in Huntington’s disease 
patients based on a paper in Journal of Clinical Investigation.(Husby, Li et al. 1977) 
Another Journal of Clinical Investigation paper found that there is hypersensitivity to 
antigens derived from brain tissue of patients with Huntington’s disease.(Walls and 
Ruwoldt 1984) In a Science paper, cellular immunity mediator: migration inhibitory 
factor is also up-regulated in Huntington’s patients.(Barkley, Hardiwidjaja et al. 1977) 
MIF can play an important role in TH17 immunity.(Stojanovic, Cvjeticanin et al. 2009) 
In a paper of Clinical Chemistry and Laboratory Medicine, elevated IgM, IgA, sTNF-R, 
sIL-2-R, and complement C3 were detected in Huntington’s disease patients’ 
serum.(Leblhuber, Walli et al. 1998) iNOS and peroxides, the effector molecules of 
TH17, can contribute to the toxicity of Huntington’s disease.(Browne and Beal 2006) 
Complements are up-regulated in Huntington’s disease.(Singhrao, Neal et al. 1999) In 
addition, lymphocytes isolated from Huntington’s patients can react with the 
antigens from Huntington’s frontal lobe grey matter. According to another paper 
published in Journal of Experimental Medicine, pathogenic immune activation was 
noted before clinical onset of Huntington’s disease.(Bjorkqvist, Wild et al. 2008) In 
this paper, highly up-regulated TH17 cytokines including IL-6 and IL-8 were found in 
Huntington’s disease patients’ serum. In addition, there is positive correlation 
between serum TNFα and IL-8 levels and Huntington’s disease severity. Huntington’s 
disease microglia are overactive to secrete IL-6 when stimulated compared to healthy 
control.(Tai, Pavese et al. 2007) Significantly up-regulation of IL-6, IL-8, and TNF-α are 
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found in postmortem Huntington’s disease striatal tissue compared to normal control. 
In addition, there is positive correlation of IL-6 and IL-8 concentration between CSF 
and plasma. Second, we also see immune dysfunction of Huntington’s disease in 
animal models. According to the above JEM paper, abnormal up-regulation of 
proinflammatory cytokines are noted in R6/2 and Hdh Huntington’s disease mice 
model. Suppression of NFkB, a key mediator in immunity, can reduce neuron-toxicity 
in brain of Huntington’s disease transgenic mice. In a proteomic study, TH17 
molecules such as IL-6, complements, and alpha-2-macroglobulin (an acute response 
protein) are increased in R6/2 mice and Huntington patients’ CSF.(Dalrymple, Wild et 
al. 2007) Third, fetal neural grafts to the brain of Huntington’s disease patients cause 
strong immune rejection.(Bachoud-Levi, Gaura et al. 2006; Krystkowiak, Gaura et al. 
2007) That means autoimmunity can play a key role in Huntington’s disease progress. 
HLA-DR polymorphism is related to the incidence of Huntington’s disease.(McGeer, 
Itagaki et al. 1988) Huntingtin R6/2 transgenic mice can easily develop autoimmune 
diabetes.(Hurlbert, Zhou et al. 1999; Hansson, Nylandsted et al. 2003) Complement 
overactivation is found in Huntington’s disease, too.(Singhrao, Neal et al. 1999) In 
addition, elevated TH17 cytokine IL-23 is found in Huntington’s patients.(Forrest, 
Mackay et al. 2010) By PET image study, microglia overactivity is noted in 
Huntington’s disease patients.(Pavese, Gerhard et al. 2006) In several important 
clinical trials, we can also find out that host immune reaction plays an important role 
in the pathogenesis of Huntington’s disease. In a paper in Lancet Neurology, fetal 
graft transplanted into striatum can improve the symptoms of Huntington’s patients 
within four years.(Bachoud-Levi, Gaura et al. 2006) However, dystonia and motor 
disability developed after the four year period, and the symptoms of Huntington’s 
disease still advanced. In another paper in PLOS one, fetal graft transplanted into 
striatum can cause immune ejection in Huntington’s patients even the HLA antigen is 
matched.(Krystkowiak, Gaura et al. 2007) These evidences both show that 
autoimmune reaction plays an important role in Huntington’s disease. If there are 
still autoimmune T or B cells against mutant Huntingtin in patients, these TH17 
immune cells will still produce cytokines such as IL-1 or TNF-α to damage the 
striatum neuron cells. Thus, the fetal grafts are still damaged, and the symptoms of 
Huntington’s disease are still in progress. Thus, vaccination against Huntingtin or fetal 
graft transplantation is a wrong therapeutic strategy. The successful strategy will be 
to induce immune tolerance for the mutant Hungtingtin. It is also possible to use 
immunosuppressants such as NSAID or IVIG or steroid to treat Huntington’s disease. 
It is noted that there is reflective elevation of cortisol in Huntington’s disease 
patients. It implies that there is certain regulatory response to suppress the overt 
autoimmunity in Huntington’s disease patients. In rat models, immunosuppressants 
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cyclosporine A or FK506 can suppress the symptoms and signs of Huntington’s 
disorder.(Kumar, Kalonia et al. 2010) Several studies also showed that minocycline, an 
immunosuppressant to suppress CD4 T cell, macrophage, and IL-6, can be used to 
treat Huntington’s disease, Amyotrophic Lateral Sclerosis, and another TH17 
autoimmune disorder: Rheumatoid arthritis.(Chen, Ona et al. 2000; Zanjani, 
Sabetkasaei et al. 2006; Szeto, Pomerantz et al. 2011) In an Italian research, 
dexamethasone can improve the symptoms and signs of Huntington’s disease.(Nuti, 
Maremmani et al. 1991; Bonuccelli, Nuti et al. 1992) I sincerely hope this paper can 
provide a new view for preventing and treating the detrimental Huntington’s disease.  
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Figure legends: 
Figure 1. RMA express plots for Huntington’s disease peripheral leukocytes 
1-A NUSE plot for Huntington’s disease peripheral leukocytes 
1-B RLE plot for Huntington’s disease peripheral leukocytes 
1-C RLE-NUSE multiplot for Huntington’s disease peripheral leukocytes 
1-D RLE-NUSE T2 plot for Huntington’s disease peripheral leukocytes 
 
Figure 2. RMA express plots for healthy control peripheral leukocytes 
2-A NUSE plot for healthy control peripheral leukocytes 
2-B RLE plot for healthy control peripheral leukocytes 
2-C RLE-NUSE multiplot for healthy control peripheral leukocytes 
2-D RLE-NUSE T2 plot for healthy control peripheral leukocytes 
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Figure 1-A. 
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Figure 1-B 
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Figure 1-C 
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Figure 1-D 
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Figure 2-A 
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Figure 2-B 
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Figure 2-C 
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Figure 2-D 
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Table 1. Ubiquitin related gene down-regulation in caudate nucleus of Huntington’s 
dz 
Probeset Pvalue Arrow FoldChange Gene Description 
201345_s_at 5.39E-04 down 1.2457378 UBE2D2 ubiquitin-conjugating enzyme E2D 2  
201387_s_at 1.72E-06 down 1.9284481 UCHL1 ubiquitin carboxyl-terminal esterase L1 
201523_x_at 1.04E-04 down 1.2343123 UBE2N ubiquitin-conjugating enzyme E2N  
201535_at 1.52E-07 down 1.4067264 UBL3 ubiquitin-like 3 
202334_s_at 2.19E-04 down 1.2670013 UBE2B ubiquitin-conjugating enzyme E2B  
202346_at 5.40E-04 down 1.3563721 UBE2K ubiquitin-conjugating enzyme E2K 
203109_at 1.38E-06 down 1.3363814 UBE2M ubiquitin-conjugating enzyme E2M 
207365_x_at 1.52E-05 up 1.2665428 USP34 ubiquitin specific peptidase 34 
209096_at 6.18E-05 down 1.3142167 UBE2V2 ubiquitin-conjugating enzyme E2 v2 
211763_s_at 1.06E-05 down 1.5108057 UBE2B ubiquitin-conjugating enzyme E2B  
212600_s_at 7.67E-05 down 1.2951877 UQCRC2 ubiquinol-cyt c reductase core protein II 
212751_at 4.65E-05 down 1.5347109 UBE2N ubiquitin-conjugating enzyme E2N  
212980_at 5.02E-04 up 1.3405594 USP34 ubiquitin specific peptidase 34 
220419_s_at 1.38E-09 down 1.4891654 USP25 ubiquitin specific peptidase 25 
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Table 2. Proteasomes down-regulation in caudate nucleus of Huntington’s disease 
Probeset Pvalue Arrow Fold Gene Description 
200786_at 3.47E-06 down 1.3381835 PSMB7 proteasome subunit, beta type, 7 
200820_at 9.05E-05 down 1.2278717 PSMD8 proteasome 26Ssubunit, non-ATPase, 8 
200987_x_at 6.55E-05 down 1.2296844 PSME3 proteasome activator subunit 3  
201068_s_at 0.006757 down 1.2186952 PSMC2 proteasome 26S subunit, ATPase, 2 
201198_s_at 1.29E-04 down 1.2277398 PSMD1 proteasome 26Ssubunit, non-ATPase, 1 
201267_s_at 6.59E-08 down 1.585018 PSMC3 proteasome 26S subunit, ATPase, 3 
201317_s_at 0.003369 down 1.2717055 PSMA2 proteasome subunit, alpha type, 2 
201388_at 1.86E-05 down 1.2290112 PSMD3 proteasome 26Ssubunit, non-ATPase, 3 
201532_at 0.006441 down 1.3514961 PSMA3 proteasome subunit, alpha type, 3 
201676_x_at 7.75E-06 down 1.321411 PSMA1 proteasome subunit, alpha type, 1 
202353_s_at 1.50E-04 down 1.2689921 PSMD12 proteasome 26Ssubunit non-ATPase12 
209040_s_at 2.15E-04 up 1.2915218 PSMB8 proteasome subunit, beta type, 8  
210759_s_at 1.16E-05 down 1.3613613 PSMA1 proteasome subunit, alpha type, 1 
211746_x_at 2.62E-05 down 1.3475449 PSMA1 proteasome subunit, alpha type, 1 
212296_at 6.52E-05 down 1.3455269 PSMD14 proteasome 26Ssubunit,nonATPase, 14 
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Table 3. Cyclophilin/FKBP down-regulation in caudate nucleus of Huntington’s 
disease 
FK506BP 
Probeset Pvalue Arrow FoldChange Gene Description 
FKBP 
200709_at 1.48E-06 down 1.7381911 FKBP1A FK506 binding protein 1A 
204560_at 0.004704 up 1.3354243 FKBP5 FK506 binding protein 5 
206857_s_at 1.52E-07 down 2.101522 FKBP1B FK506 binding protein 1B 
209931_s_at 4.00E-08 down 1.4627817 FKBP1B FK506 binding protein 1B 
210186_s_at 1.22E-07 down 1.9794762 FKBP1A FK506 binding protein 1A 
214119_s_at 2.10E-08 down 1.8854779 FKBP1A FK506 binding protein 1A 
218003_s_at 1.73E-04 down 1.273593 FKBP3 FK506 binding protein 3 
219117_s_at 2.43E-10 down 1.6172751 FKBP11 FK506 binding protein 11 
Cyclophilin 
211978_x_at 6.36E-06 down 1.247459 PPIA peptidylprolyl isomeraseA 
212661_x_at 3.35E-06 down 1.2826694 PPIA peptidylprolyl isomeraseA 
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Table 4. MHC gene up-regulation in caudate nucleus of Huntington’s disease 
Probeset Pvalue Arrow Fold Gene Description 
200904_at 0.006 up 1.29 HLA-E major histocompatibility complex, I,E 
201137_s_at 0.000 up 1.54 HLA-DPB1 major histocompatibility complex,II, DPβ1 
204670_x_at 0.007 up 1.32 HLA-DRB1/ major histocompatibility complexII, DRβ1/ 
209312_x_at 0.002 up 1.58 HLA-DRB1/ major histocompatibility complexII, DRβ1/ 
210982_s_at 0.009 up 1.55 HLA-DRA major histocompatibility complex,II, DRα 
211654_x_at 0.003 up 1.26 HLA-DQB1 major histocompatibility complex,II, DQβ1 
211656_x_at 0.001 up 1.21 HLA-DQB1 major histocompatibility complex II, DQβ1 
211990_at 0.009 up 1.50 HLA-DPA1 major histocompatibility complex,II, DPα1 
211991_s_at 0.040 up 1.33 HLA-DPA1 major histocompatibility complex,II, DPα1 
212671_s_at 0.008 up 1.38 HLA-DQA1/ major histocompatibility complexII, DQα1/ 
212998_x_at 0.007 up 1.29 HLA-DQB1 major histocompatibility complex,II, DQβ1 
215193_x_at 0.006 up 1.48 HLA-DRB1/ major histocompatibility complexII, DRβ1/ 
215313_x_at 0.016 up 1.20 HLA-A major histocompatibility complex, I, A 
216526_x_at 0.026 up 1.21 HLA-C major histocompatibility complex, I, C 
217478_s_at 0.011 up 1.34 HLA-DMA major histocompatibility complex,II, DMα 
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Table 5. Differential regulation of heat shock proteins in caudate nucleus of 
Huntington’s disease 
Probeset Pvalue Arrow Fold Gene Description 
202415_s_at 0.000 down 1.30 HSPBP1 heat shock 70kDcoprotein1 
202557_at 0.001 down 1.32 HSPA13 heat shock 70kD13 
202558_s_at 0.001 down 1.34 HSPA13 heat shock 70kD13 
204720_s_at 0.007 down 1.34 DNAJC6 Hsp40 homologC6 
206976_s_at 0.001 down 1.58 HSPH1 heat shock 105kDa/110kDa1 
208687_x_at 0.018 down 1.26 HSPA8 heat shock 70kDa protein 8 
208744_x_at 0.000 down 1.59 HSPH1 heat shock 105kDa/110kDa 1 
209157_at 0.000 down 1.40 DNAJA2 Hsp40 homologA2 
210338_s_at 0.004 down 1.46 HSPA8 heat shock 70kDa protein 8 
214359_s_at 0.009 down 1.26 HSP90AB1 heat shock protein 90kDaB1 
214434_at 0.000 down 1.48 HSPA12A heat shock 70kDa protein 12A 
218976_at 0.000 down 1.49 DNAJC12 Hsp40 homolog,C12 
200666_s_at 0.028 up 1.47 DNAJB1 Hsp40 homologB1 
200799_at 0.002 up 1.65 HSPA1A heat shock 70kDa protein 1A 
200800_s_at 0.003 up 1.84 HSPA1A/B heat shock 70kDa 1A/B 
201841_s_at 0.000 up 2.11 HSPB1 heat shock 27kDa protein 1 
202500_at 0.000 up 1.37 DNAJB2 Hsp40 homolog, B2 
202581_at 0.001 up 2.12 HSPA1A/B heat shock 70kDa 1A/B 
207714_s_at 0.004 up 1.31 SERPINH1 heat shock protein 47 
209015_s_at 0.029 up 1.28 DNAJB6 Hsp40 homolog,B6 
211538_s_at 0.003 up 1.27 HSPA2 heat shock 70kDa protein 2 
218435_at 0.001 up 1.21 DNAJC15 Hsp40 homolog,C15 
221667_s_at 0.000 up 1.93 HSPB8 heat shock 22kDa protein 8 
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Table 6. TLR up-regulation in caudate nucleus of Huntington’s disease patients 
Probeset Pvalue Arrow Fold Gene Description 
210166_at 4.55E-05 up 1.284263 TLR5 toll-like receptor 5 
217930_s_at 3.61E-04 down 1.238067 TOLLIP toll interacting protein 
221571_at 1.29E-04 up 1.218646 TRAF3 TNFreceptor-associated factor 3 
201743_at 0.007868 up 1.517295 CD14 CD14 molecule 
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Table 7. Huntingtin, alpha synuclein, and APP expression in caudate nucleus of 
Huntington’s disease 
Probeset Pvalue Arrow Fold Gene Description 
204466s_at 6.19E-06 down 1.623331 SNCA synuclein, alpha  
204467s_at 3.56E-07 down 1.333884 SNCA synuclein, alpha  
207827x_at 0.001864 down 1.26331 SNCA synuclein, alpha  
211546x_at 1.15E-04 down 1.23024 SNCA synuclein, alpha  
214875x_at 1.94E-04 down 1.216281 APLP2 amyloid beta precursor-like protein 2 
214953s_at 8.09E-04 down 1.261554 APP amyloid beta precursor protein 
217756x_at 5.80E-05 up 1.222023 HYPK Huntingtin interacting protein K 
209558s_at 4.62E-06 up 1.306876 HIP1R huntingtin interacting protein 1 relate 
38340_at 9.10E-06 up 1.288642 HIP1R huntingtin interacting protein 1 relate 
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Table 8. TH17 Cytokine & receptor up-regulation in caudate nucleus of Huntington’s 
disease patients 
Probeset Pvalue Arrow Fold Gene Description 
201922_at 5.72E-04 down 1.24735 TINP1 TGF beta-inducible nuclear protein 1 
204352_at 3.17E-04 down 1.283694 TRAF5 TNF receptor-associated factor 5 
205707_at 1.54E-06 down 1.230763 IL17RA interleukin 17 receptor A 
206172_at 5.80E-06 down 1.344398 IL13RA2 interleukin 13 receptor, alpha 2 
201587s_at 5.73E-05 up 1.224924 IRAK1 interleukin1receptor-associatedkinase 1 
201887_at 3.44E-06 up 1.538919 IL13RA1 interleukin 13 receptor, alpha 1 
202727s_at 2.42E-06 up 1.280171 IFNGR1 interferon gamma receptor 1 
202729s_at 4.55E-05 up 1.251086 LTBP1 latent TGFb binding protein 1 
203085s_at 1.14E-05 up 1.286053 TGFB1 transforming growth factor, beta 1 
203104_at 2.31E-04 up 1.406054 CSF1R colony stimulating factor 1 receptor 
203233_at 6.38E-04 up 1.294538 IL4R interleukin 4 receptor 
203313s_at 5.87E-07 up 1.618584 TGIF1 TGFB-induced factor homeobox 1 
204731_at 1.08E-05 up 1.403113 TGFBR3 TGF, beta receptor III 
204863s_at 0.001925 up 1.272306 IL6ST interleukin 6 signal transducer  
206315_at 0.003443 up 1.348233 CRLF1 cytokine receptor-like factor 1 
207643s_at 2.03E-04 up 1.49925 TNFR1A tumor necrosis factor receptor1A 
209651_at 4.62E-04 up 1.258696 TGFB1I1 TGF beta 1 induce1 
209747_at 0.001409 up 1.264362 TGFB3 transforming growth factor, beta 3 
210314x_at 0.002619 up 1.220112 TNFSF13 tumor necrosis factor 13 
212195_at 1.78E-05 up 1.300436 IL6ST interleukin 6 signal transducer 
219255x_at 1.91E-06 up 1.586974 IL17RB interleukin 17 receptor B 
219922s_at 2.37E-04 up 1.337614 LTBP3 latent TGFb binding protein 3 
220407s_at 0.002428 up 1.226877 TGFB2 transforming growth factor, beta 2 
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Table 9. TH17 related transcription factors up-regulation in caudate nucleus of 
Huntington’s disease 
Probeset Pvalue Arrow Fold Gene Decription 
203973_s_at 0.004461 up 2.109633 CEBPD CCAAT/enhancerbinding protein delta 
201502_s_at 3.22E-05 up 2.093148 NFKBIA NFkB inhibitor, alpha 
209189_at 0.009862 up 1.668841 FOS v-fos homolog 
203685_at 1.98E-06 up 1.655964 BCL2 B-cell CLL/lymphoma 2 
201464_x_at 0.001406 up 1.446249 JUN jun oncogene 
212501_at 0.021496 up 1.370979 CEBPB CCAAT/enhancer binding protein beta 
201465_s_at 0.003767 up 1.341294 JUN jun oncogene 
208991_at 0.001693 up 1.317737 STAT3 STAT 3 (acute-phase response factor) 
211105_s_at 5.22E-05 up 1.281264 NFATC1 nuclear factor of activated T-cells c 1 
201328_at 0.007909 up 1.243003 ETS2 v-ets homolog 2 (avian) 
209341_s_at 5.57E-05 up 1.204966 IKBKB inhibitor of KappaB, kinase beta 
206118_at 3.70E-04 down 1.223148 STAT4 STAT 4 
218284_at 6.97E-05 down 1.211594 SMAD3 SMAD family member 3 
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Table 10. TH17 effector molecule up-regulation in caudate nucleus of Huntington’s 
disease patients 
Probeset Pvalue Arrow Fold Gene Description 
Complement 
202953_at 0.001778 up 1.761679 C1QB complement component 1, q B chain 
208451_s_at 2.49E-07 up 2.545643 C4A/4B complement component 4A /4B 
208747_s_at 2.06E-04 up 1.6251 C1S complement component 1, s  
208910_s_at 0.007279 down 1.289107 C1QBP complement component 1q binding protein 
212067_s_at 5.44E-04 up 1.487101 C1R complement component 1, r 
214428_x_at 4.28E-07 up 2.287758 C4A/4B complement component 4A/ 4B 
215388_s_at 0.006918 up 1.340977 CFH/HR1 complement factor H /H-related 1 
217767_at 7.93E-06 up 2.181982 C3 complement component 3 
218232_at 3.58E-04 up 1.758813 C1QA complement component 1, q A chain 
S100BP 
202917_s_at 0.048478 up 1.601384 S100A8 S100calcium binding protein A8 
203186_s_at 9.38E-06 up 1.219246 S100A4 S100calcium binding protein A4 
209686_at 0.037697 up 1.212993 S100B S100 calcium binding protein B 
Fc receptor 
203240_at 0.007898 up 1.264528 FCGBP  Fc fragment of IgG binding protein 
204232_at 0.011859 up 1.219916 FCER1G Fc fragment of IgE receptor gamma 
214511_x_at 0.041031 up 1.369042 FCGR1B Fc fragment of IgG receptor (CD64) 
216950_s_at 0.031795 up 1.293124 FCGR1C/A Fc fragment of IgG receptor (CD64) 
218831_s_at 7.97E-08 up 1.285617 FCGRT Fc fragment of IgG,transporter, alpha 
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Table 11. Apoptosis molecule up-regulation in caudate nucleus of Huntington’s 
disease patients 
Probeset Pvalue Arrow Fold Gene Description 
203618_at 8.50E-06 down 1.296034 FAIM2 Fas apoptotic inhibitory molecule 2 
203619_s_at 0.005638 down 1.282231 FAIM2 Fas apoptotic inhibitory molecule 2 
211316_x_at 9.02E-09 up 1.327713 CFLAR CASP8 and FADD apoptosis regulator 
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Table 12. Up-regulation of TH17 related cytokines in peripheral leukocytes of 
Huntington’s disease patients 
Probeset Fold Arrow Pvalue Gene Description 
39402_at 4.360861 up 0.037872 IL1B interleukin 1, beta 
211506_s_at 2.718258 up 0.048833 IL8 interleukin 8 
201109_s_at 1.666708 up 0.015589 THBS1 thrombospondin 1 
201110_s_at 1.59916 up 0.040584 THBS1 thrombospondin 1 
210405_x_at 1.344011 up 0.022787 TNFRSF10B TNFR member 10b 
209295_at 1.330597 up 0.023801 TNFRSF10B TNFR member 10b 
214950_at 1.320244 up 0.00964 IL9R  interleukin 9 receptor  
201107_s_at 1.231763 up 0.023031 THBS1 thrombospondin 1 
224555_x_at 1.188561 up 0.049967 IL1F7 interleukin 1 member 7 
215775_at 1.15913 up 0.037228 THBS1 Thrombospondin 1 
236186_x_at 1.124306 up 0.013195 IL17RE interleukin 17 receptor E 
1553740_a_at 1.119031 up 0.008364 IRAK2 interleukin-1 R-associated kinase 2 
207160_at 1.109904 up 0.00665 IL12A interleukin 12A 
229401_at 1.10332 up 0.02878 IL17RE Interleukin 17 receptor E 
220056_at 1.103219 up 0.03977 IL22RA1 interleukin 22 receptor, alpha 1 
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Table 13. Up-regulation of Th17 related transcription factors in peripheral leukocytes 
in Huntington’s disease patients 
Probeset Fold Arrow Pvalue Gene Description 
201502_s_at 2.165705 up 0.033956 NFKBIA NFkB inhibitor, alpha 
223217_s_at 2.095656 up 0.003202 NFKBIZ NFkB inhibitor, zeta 
223218_s_at 1.774534 up 0.020231 NFKBIZ NFkB inhibitor, zeta 
225262_at 1.765213 up 0.026004 FOSL2 FOS-like antigen 2 
207535_s_at 1.694145 up 0.005265 NFKB2 NFkB 2 (p49/p100) 
1553042_a_at 1.399326 up 0.038525 NFKBID NFkB inhibitor, delta 
218880_at 1.274277 up 0.030736 FOSL2 FOS-like antigen 2 
214398_s_at 1.213314 up 0.041044 IKBKE inhibitor of kappa B, kinase epsilon 
223439_at 1.312243 down 0.027207 NKAP NFKB activating protein 
235725_at 1.215126 down 0.023413 SMAD4 SMAD family member 4 
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Table 14. Up-regulation of TH17 related effector molecules in peripheral leukocytes 
in Huntington’s patients 
Probeset Fold Arrow Pvalue Gene Description 
Complement 
201925_s_at 1.261398 up 0.034054 CD55 decay accelerating factor 
201926_s_at 1.330632 up 0.00963 CD55 decay accelerating factor 
210324_at 1.1651 up 0.018821 C8G complement 8 gamma 
1555950_a_at 1.291796 up 0.007873 CD55 decay accelerating factor 
211574_s_at 1.281112 up 0.033621 CD46 complement regulatory protein 
Defensin 
1568377_x_at 1.187424 up 0.043945 DEFB124 defensin, beta 124 
Chemokine 
209774_x_at 3.643812 up 0.036962 CXCL2 CXC chemokine ligand 2 
207900_at 1.162655 up 0.017054 CCL17 chemokine (C-C motif) ligand 17 
207861_at 1.144102 up 0.034251 CCL22 chemokine (C-C motif) ligand 22 
Lysozyme 
202032_s_at 1.240601 up 0.00368 MAN2A2 mannosidase, alpha2A2 
Apoptosis 
207181_s_at 1.312915 down 0.037484 CASP7 caspase 7 
208050_s_at 1.303875 up 0.008209 CASP2 caspase 2 
211317_s_at 1.433529 up 0.049667 CFLAR CASP8 and FADD-like regulator 
211862_x_at 1.532954 up 0.03114 CFLAR CASP8 and FADD-like regulator 
211888_x_at 1.12303 up 0.009932 CASP10 caspase 10 
Prostanglandin 
210374_x_at 1.145153 up 0.013688 PTGER3 prostaglandin E receptor 3 
Fc receptor 
207674_at 1.176423 up 0.041686 FCAR Fc fragment of IgA receptor 
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